The IntelliVue MX850 monitor shows the patient’s vital signs. Philips recently obtained FDA 510(k) clearance for its IntelliVue MX750 and MX850 devices.Image source: Philips
One year after obtaining emergency approval to use them during the pandemic, Royal Philips’ latest two patient monitors are now approved by the Food and Drug Administration.The agency Recently obtained a 510(k) license Philips’ IntelliVue MX750 and MX850 are designed to provide real-time information about the vital signs of patients and support remote monitoring in a hospital environment.
U.S. Food and Drug Administration Initially granted Philips emergency use authorization The equipment last April, shortly after the start of the Covid-19 pandemic. Given that these devices can be used to remotely monitor hospitalized patients, the purpose is to use them to observe the vital signs of hospitalized Covid-19 patients without exposing medical staff to the virus when masks and other protective equipment are scarce.
Philips said these devices enter encrypted patient data into the hospital’s EMR, providing a real-time view of their condition. They can be connected to equipment such as IV pumps, anesthesia machines and ventilators. These monitors can also support clinical decision support tools, such as a tool developed by Philips that displays changes in vital signs and provides background information about the patient’s condition.
The FDA permit only includes two displays, but the emergency use authorization also includes additional displays and modular server racks. The entire system has been used in Europe since it received the CE mark in 2019.
